1031 related articles for article (PubMed ID: 7563202)
1. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection.
Chen KG; Jaffrézou JP; Fleming WH; Durán GE; Sikic BI
Cancer Res; 1994 Sep; 54(18):4980-7. PubMed ID: 7915196
[TBL] [Abstract][Full Text] [Related]
3. Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis.
Jaffrézou JP; Chen KG; Durán GE; Kühl JS; Sikic BI
J Natl Cancer Inst; 1994 Aug; 86(15):1152-8. PubMed ID: 8028036
[TBL] [Abstract][Full Text] [Related]
4. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Kim WJ; Kakehi Y; Yoshida O
Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
[TBL] [Abstract][Full Text] [Related]
5. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
Eijdems EW; Zaman GJ; de Haas M; Versantvoort CH; Flens MJ; Scheper RJ; Kamst E; Borst P; Baas F
Br J Cancer; 1995 Aug; 72(2):298-306. PubMed ID: 7640209
[TBL] [Abstract][Full Text] [Related]
6. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
8. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
9. Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins.
Chen G; Durán GE; Steger KA; Lacayo NJ; Jaffrézou JP; Dumontet C; Sikic BI
J Biol Chem; 1997 Feb; 272(9):5974-82. PubMed ID: 9038218
[TBL] [Abstract][Full Text] [Related]
10. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells.
Chen GK; Durán GE; Mangili A; Beketic-Oreskovic L; Sikic BI
Br J Cancer; 2000 Oct; 83(7):892-8. PubMed ID: 10970691
[TBL] [Abstract][Full Text] [Related]
11. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.
Li J; Xu LZ; He KL; Guo WJ; Zheng YH; Xia P; Chen Y
Breast Cancer Res; 2001; 3(4):253-63. PubMed ID: 11434876
[TBL] [Abstract][Full Text] [Related]
12. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
13. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
Hasegawa S; Abe T; Naito S; Kotoh S; Kumazawa J; Hipfner DR; Deeley RG; Cole SP; Kuwano M
Br J Cancer; 1995 May; 71(5):907-13. PubMed ID: 7734314
[TBL] [Abstract][Full Text] [Related]
14. Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Naito S; Hasegawa S; Yokomizo A; Koga H; Kotoh S; Kuwano M; Kumazawa J
Jpn J Cancer Res; 1995 Nov; 86(11):1112-8. PubMed ID: 8567404
[TBL] [Abstract][Full Text] [Related]
15. Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance.
Versantvoort CH; Withoff S; Broxterman HJ; Kuiper CM; Scheper RJ; Mulder NH; de Vries EG
Int J Cancer; 1995 May; 61(3):375-80. PubMed ID: 7729950
[TBL] [Abstract][Full Text] [Related]
16. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
[TBL] [Abstract][Full Text] [Related]
17. MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro.
Warmann S; Göhring G; Teichmann B; Geerlings H; Fuchs J
J Pediatr Surg; 2002 Nov; 37(11):1579-84. PubMed ID: 12407543
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.
Abe T; Koike K; Ohga T; Kubo T; Wada M; Kohno K; Mori T; Hidaka K; Kuwano M
Br J Cancer; 1995 Aug; 72(2):418-23. PubMed ID: 7640227
[TBL] [Abstract][Full Text] [Related]
19. BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma.
Yanagisawa T; Newman A; Coley H; Renshaw J; Pinkerton CR; Pritchard-Jones K
Br J Cancer; 1999 Jun; 80(8):1190-6. PubMed ID: 10376971
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
Stahl M; Kasimir-Bauer S; Harstrick A
Anticancer Drugs; 1997 Aug; 8(7):671-6. PubMed ID: 9311443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
